Final results from TAIL: updated long-term efficacy of atezolizumab in a diverse population of patients with previously treated advanced non-small cell lung cancer

• Published in: Journal for immunotherapy of cancer 2022-11, Vol.10 (11), p.e005581
• Main Authors: Ardizzoni, Andrea, Azevedo, Sergio, Rubio-Viqueira, Belen, Rodriguez-Abreu, Delvys, Alatorre-Alexander, Jorge, Smit, Hans J M, Yu, Jinming, Syrigos, Konstantinos, Höglander, Elen, Kaul, Monika, Tolson, Jonathan, Hu, Youyou, Vollan, Hans Kristian, Newsom-Davis, Thomas
• Format: Article
• Language: English
• Subjects: Aged; Antibodies, Monoclonal, Humanized - pharmacology; Antibodies, Monoclonal, Humanized - therapeutic use; Cancer; Carcinoma, Non-Small-Cell Lung - drug therapy; Commentary; Humans; Immunotherapy; Lung cancer; Lung Neoplasms; Lung Neoplasms - drug therapy; Monoclonal antibodies; Progression-Free Survival; Targeted cancer therapy
• ISSN: 2051-1426; 2051-1426
• DOI: 10.1136/jitc-2022-005581

In patients with previously treated advanced or metastatic non-small cell lung cancer (NSCLC), atezolizumab therapy improves survival with manageable safety. The open-label, single-arm phase III/IV TAIL study (NCT03285763) evaluated atezolizumab monotherapy in patients with previously treated NSCLC, including those with Eastern Cooperative Oncology Group performance status of 2, severe renal impairment, prior anti-programmed death 1 therapy, autoimmune disease, and age ≥75 years. Patients received atezolizumab intravenously (1200 mg) every 3 weeks. At data cut-off for final analysis, the median follow-up was 36.1 (range 0.0–42.3) months. Treatment-related (TR) serious adverse events (SAEs) and TR immune-related adverse events (irAEs) were the coprimary endpoints. Secondary endpoints included overall survival (OS), progression-free survival (PFS), overall response rate, and duration of response. Safety and efficacy in key patient subgroups were also assessed. TR SAEs and TR irAEs occurred in 8.0% and 9.4% of patients, respectively. No new safety signals were documented. In the overall population, median OS and PFS (95% CI) were 11.2 months (8.9 to 12.7) and 2.7 months (2.3 to 2.8), respectively. TAIL showed that atezolizumab has a similar risk-benefit profile in clinically diverse patients with previously treated NSCLC, which may guide treatment decisions for patients generally excluded from pivotal clinical trials.